Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CIT | O14578 | 1/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.54 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.54 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.54 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.54 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.54 |
| ▸ | MYLK2 | Q9H1R3 | 1/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.54 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.54 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.54 |
| ▸ | TLK1 | Q9UKI8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20181537 | 1.00 | AAK1 (1.00) | AAK1CYP3A4CITDAPK3JAK2 | |
| SCHEMBL19946054 | 0.93 | AAK1 (0.86) | AAK1 | |
| SCHEMBL20176343 | 0.90 | AAK1 (1.00) | AAK1 | |
| SCHEMBL20181587 | 0.90 | AAK1 (1.00) | AAK1 | |
| SCHEMBL17971442 | 0.84 | AAK1 (0.72) | AAK1CYP3A4CITDAPK3JAK2 | |
| SCHEMBL20164814 | 0.83 | AAK1 (1.00) | AAK1 | |
| SCHEMBL20164815 | 0.83 | AAK1 (1.00) | AAK1 | |
| SCHEMBL20981517 | 0.83 | AAK1 (0.72) | AAK1 | |
| SCHEMBL19946111 | 0.83 | AAK1 (0.86) | AAK1 | |
| SCHEMBL20176334 | 0.82 | AAK1 (0.87) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174044-B2 | Fused pyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174044-B2 | Fused pyridines as kinase inhibitors | AAK1, NCK1, ADCK1 | AAK1 1/4885CYP3A4 4720/4885CIT 969/4885 |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | AAK1, NCK1, ADCK1 | AAK1 1/4885CYP3A4 4720/4885CIT 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.